Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Farmers Insurance
Argus Health
Moodys
Johnson and Johnson
Baxter
Queensland Health
Dow
Teva
Cipla

Generated: August 20, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 011856

« Back to Dashboard
NDA 011856 describes SOLU-MEDROL, which is a drug marketed by Pharmacia And Upjohn and is included in one NDA. It is available from five suppliers. Additional details are available on the SOLU-MEDROL profile page.

The generic ingredient in SOLU-MEDROL is methylprednisolone sodium succinate. There are forty drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the methylprednisolone sodium succinate profile page.

Summary for NDA: 011856

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)
Inflammatory Bowel Disease Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 011856

Suppliers and Packaging for NDA: 011856

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SOLU-MEDROL
methylprednisolone sodium succinate
INJECTABLE;INJECTION 011856 NDA Pharmacia and Upjohn Company LLC 0009-0003 0009-0003-02 1 VIAL in 1 CARTON (0009-0003-02) > 4 mL in 1 VIAL
SOLU-MEDROL
methylprednisolone sodium succinate
INJECTABLE;INJECTION 011856 NDA Pharmacia and Upjohn Company LLC 0009-0018 0009-0018-20 1 VIAL in 1 CARTON (0009-0018-20) > 8 mL in 1 VIAL

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 40MG BASE/VIAL
Approval Date:Approved Prior to Jan 1, 1982TE:APRLD:Yes

Summary for product number 004

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 125MG BASE/VIAL
Approval Date:Approved Prior to Jan 1, 1982TE:APRLD:Yes

Summary for product number 005

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 500MG BASE/VIAL
Approval Date:Approved Prior to Jan 1, 1982TE:APRLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Cerilliant
Johnson and Johnson
Federal Trade Commission
Deloitte
Cantor Fitzgerald
AstraZeneca
Queensland Health
Daiichi Sankyo
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot